New drug duo targets Hard-to-Treat head and neck cancer

NCT ID NCT06194656

Recruiting now Disease control Sponsor: Shanghai Institute Of Biological Products Source: ClinicalTrials.gov ↗

First seen Jun 27, 2026 · Last updated Jun 27, 2026

Summary

This phase II trial tests a new drug called SIBP-03, given together with cetuximab, for people with advanced head and neck cancer that has returned or spread. The study will enroll 81 adults who have already tried immunotherapy and platinum chemotherapy. The goal is to see if the combination can shrink tumors and control the disease longer.

What this could mean

Our plain-language read of the trial. This is informational only — not medical advice or a prediction.

Active substance: SIBP-03 (HER3 monoclonal antibody) combined with cetuximab
What this could lead to: If it works, this could offer a new treatment option for people with advanced head and neck cancer that has stopped responding to standard therapies.
What could go wrong: This is an early Phase II study with only 81 participants, so results may not apply to everyone. The combination may cause side effects or fail to shrink tumors.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for HEAD AND NECK SQUAMOUS CELL CARCINOMA are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

head and neck squamous cell carcinoma Squamous Cell Carcinoma of Head and Neck

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

HEAD AND NECK SQUAMOUS CELL CARCINOMA

Contacts and locations

Locations

Shanghai East Hospital
RECRUITING

Shanghai, Shanghai Municipality, China
Shanghai East Hospital
RECRUITING

Shanghai, Shanghai Municipality, China

More trials for these conditions

Other studies related to the condition(s) this trial covers.